Pipeline Report

Updated February 1st, 2026

BuyandBill.com Analytics Pro Features

Unlock Full Access to
BuyandBill.com Analytics

Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.

You attempted to open: Drug Pipeline Report
10+ Years of Historical Pricing Data
Unlimited Access to All Drug Pages
Comparative & Historical Drug Pricing Reports
PriceDoctoRx Self-Administered Drug Pricing
Medicare & Medicaid Claims Data
Drug Pipeline Report
Check Out New Features
Comparative Pricing Reports

Search

Descriptive Alt Text

Filters

Showing results 4,105–4,112 of 4,419
Manufacturer ▼ Drug Name Indication Stage Status Route of Administration Drug Class
TuHURA Biosciences Inc. REM-001 Cutaneous Metastatic Breast Cancer (CMBC) Phase 3 Looking for Funding Intravenous Oncology
TuHURA Biosciences Inc. REM-001 Cutaneous Metastatic Breast Cancer (CMBC) Phase 3 Looking for Funding Intravenous Oncology
TuHURA Biosciences Inc. Immune Fx (IFx-2.0) Cancer vaccine for merkel cell carcinoma (MCC) Phase 3 Ongoing Oral Oncology
TuHURA Biosciences Inc. Immune Fx (IFx-2.0) Cancer vaccine for merkel cell carcinoma (MCC) Phase 3 Ongoing Oral Oncology
TuHURA Biosciences Inc. Paxalisib (GDC-0084), VAL-083, Troriluzole, and VT1021 - (GBM AGILE) Glioblastoma (GBM) Phase 2/3 Trial Completed Oral Oncology
TuHURA Biosciences Inc. Paxalisib (GDC-0084), VAL-083, Troriluzole, and VT1021 - (GBM AGILE) Glioblastoma (GBM) Phase 2/3 Trial Completed Oral Oncology
TuHURA Biosciences Inc. VAL-083 MGMT-unmethylated Recurrent Bevacizumab Naïve Glioblastoma Multiforme (GBM) or The Adjuvant Phase 2 Ongoing Intravenous Oncology
TuHURA Biosciences Inc. VAL-083 MGMT-unmethylated Recurrent Bevacizumab Naïve Glioblastoma Multiforme (GBM) or The Adjuvant Phase 2 Ongoing Intravenous Oncology